S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:HSKAHeska Stock Price, Forecast & News

$105.76
-0.34 (-0.32 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$105.09
Now: $105.76
$106.89
50-Day Range
$89.84
MA: $96.04
$107.61
52-Week Range
$50.00
Now: $105.76
$110.90
Volume28,958 shs
Average Volume73,651 shs
Market Capitalization$998.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. Heska Corporation sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.
Read More
Heska logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.06 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HSKA
CUSIPN/A
Phone970-493-7272

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$122.66 million
Cash Flow$0.92 per share
Book Value$19.72 per share

Profitability

Net Income$-1,470,000.00

Miscellaneous

Employees347
Market Cap$998.80 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$105.76
-0.34 (-0.32 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HSKA News and Ratings via Email

Sign-up to receive the latest news and ratings for HSKA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Heska (NASDAQ:HSKA) Frequently Asked Questions

How has Heska's stock been impacted by COVID-19 (Coronavirus)?

Heska's stock was trading at $81.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HSKA stock has increased by 29.2% and is now trading at $105.76.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Heska?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Heska
.

When is Heska's next earnings date?

Heska is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Heska
.

How were Heska's earnings last quarter?

Heska Corp (NASDAQ:HSKA) released its earnings results on Tuesday, August, 4th. The medical research company reported ($0.72) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.29. Heska had a negative return on equity of 1.57% and a negative net margin of 9.57%.
View Heska's earnings history
.

What guidance has Heska issued on next quarter's earnings?

Heska updated its FY 2020 Pre-Market earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $175-185 million, compared to the consensus revenue estimate of $175.66 million.

What price target have analysts set for HSKA?

6 brokers have issued 12 month price objectives for Heska's stock. Their forecasts range from $59.00 to $116.50. On average, they expect Heska's share price to reach $91.70 in the next year. This suggests that the stock has a possible downside of 13.3%.
View analysts' price targets for Heska
.

Has Heska been receiving favorable news coverage?

News stories about HSKA stock have been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Heska earned a news sentiment score of -1.3 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Heska
.

Are investors shorting Heska?

Heska saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 556,400 shares, a decline of 18.6% from the May 31st total of 683,700 shares. Based on an average daily trading volume, of 80,400 shares, the days-to-cover ratio is presently 6.9 days.
View Heska's Short Interest
.

Who are some of Heska's key competitors?

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), NVIDIA (NVDA), Broadcom (AVGO), Biogen (BIIB), Cisco Systems (CSCO), Skyworks Solutions (SWKS), AbbVie (ABBV) and Adobe (ADBE).

Who are Heska's key executives?

Heska's management team includes the following people:
  • Mr. Kevin S. Wilson, CEO, Pres & Director (Age 47)
  • Mr. Jason A. Napolitano, COO & Chief Strategist (Age 51)
  • Ms. Catherine I. Grassman CPA, VP, Chief Accounting Officer & Corp. Controller (Age 43)
  • Dr. Nancy Wisnewski, Exec. VP of Diagnostic Operations & Product Devel. (Age 56)
  • Mr. Jason D. Aroesty, Exec. VP of International Diagnostics (Age 44)

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Who are Heska's major shareholders?

Heska's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.87%), Riverbridge Partners LLC (3.00%), FMR LLC (1.89%), Russell Investments Group Ltd. (1.10%), Bank of New York Mellon Corp (0.91%) and Principal Financial Group Inc. (0.69%). Company insiders that own Heska stock include G Irwin Gordon, Jason A Napolitano, Kevin S Wilson, Rod Lippincott, Scott Humphrey and Steve Asakowicz.
View institutional ownership trends for Heska
.

Which institutional investors are selling Heska stock?

HSKA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Riverbridge Partners LLC, Grace & White Inc. NY, PDT Partners LLC, Prudential Financial Inc., Teton Advisors Inc., and PNC Financial Services Group Inc..
View insider buying and selling activity for Heska
.

Which institutional investors are buying Heska stock?

HSKA stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., SG Americas Securities LLC, Bank of New York Mellon Corp, Principal Financial Group Inc., Russell Investments Group Ltd., Trexquant Investment LP, and UBS Group AG.
View insider buying and selling activity for Heska
.

How do I buy shares of Heska?

Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $105.76.

How big of a company is Heska?

Heska has a market capitalization of $998.80 million and generates $122.66 million in revenue each year. The medical research company earns $-1,470,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. Heska employs 347 workers across the globe.

What is Heska's official website?

The official website for Heska is www.heska.com.

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.